Bradley Jack, Warwick David
University Hospital Southampton and University of Southampton, Southampton, United Kingdom.
University Hospital Southampton and University of Southampton, Southampton, United Kingdom.
J Hand Surg Am. 2016 Jun;41(6):689-97. doi: 10.1016/j.jhsa.2016.03.003. Epub 2016 Apr 28.
To establish patient satisfaction after collagenase clostridium histolyticum (CCH) injection.
In a cross-sectional study, 213 patients who had been treated for Dupuytren disease with CCH were reviewed between 37 and 1421 days after injection.
A total of 73% of the patients were very satisfied or satisfied, and 21% were dissatisfied; 75% would probably or definitely have CCH again, whereas 17% probably or definitely would not. We found that satisfaction and willingness to undergo a second treatment decreased over time and had a negative relationship with recurrence. Dissatisfaction was greater in those with a poor initial outcome but not in those with an initial complication. Of 212 patients, 78 had previously experienced surgery for Dupuytren disease of whom 71% would prefer CCH to surgery and 15% the converse. Satisfaction shows a relationship with function as measured by both QuickDASH and the Southampton Dupuytren Scoring Scheme.
Patient satisfaction with CCH is generally high but deteriorates over time as the disease recurs. To manage patient expectation, this issue should be made explicit to patients in the consent process.
Overall satisfaction with CCH is high, with initial satisfaction rates especially good. Forewarning of complications and recurrence can help maintain satisfaction levels.
评估注射溶组织梭状芽孢杆菌胶原酶（CCH）后患者的满意度。
在一项横断面研究中，对213例接受CCH治疗掌腱膜挛缩症的患者在注射后37至1421天进行了评估。
共有73%的患者非常满意或满意，21%的患者不满意；75%的患者可能或肯定会再次接受CCH治疗，而17%的患者可能或肯定不会。我们发现，满意度和接受二次治疗的意愿随时间下降，且与复发呈负相关。初始疗效差的患者不满意程度更高，但初始有并发症的患者并非如此。在212例患者中，78例曾因掌腱膜挛缩症接受过手术，其中71%的患者更喜欢CCH而非手术，15%的患者则相反。满意度与通过QuickDASH和南安普敦掌腱膜评分方案衡量的功能相关。
患者对CCH的满意度总体较高，但随着疾病复发，满意度会随时间下降。为了管理患者预期，在知情同意过程中应向患者明确说明这一问题。
患者对CCH的总体满意度较高，初始满意度尤其好。对并发症和复发进行预先警示有助于维持满意度水平。
